Hikma Pharmaceuticals Plc Total Voting Rights (4148Y)
02 Enero 2024 - 9:24AM
UK Regulatory
TIDMHIK
RNS Number : 4148Y
Hikma Pharmaceuticals Plc
02 January 2024
Hikma Pharmaceuticals PLC
(the Company)
Total Voting Rights and Capital
LONDON, 2 January 2024 - In accordance with section 5.6.1 of the
UK Financial Conduct Authority's Disclosure Guidance and
Transparency Rules (the 'Rules') , Hikma Pharmaceuticals PLC
(LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK)
notifies the market of the following:
As at 31 December 2023, the issued share capital of the Company
comprised of 221,081,371 Ordinary Shares of 10 pence each
('Shares') with voting rights. This figure excludes 12,833,233
Shares held in treasury, which do not have voting rights.
The figure of 221,081,371 may be used by shareholders (and
others with notification obligations) as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Helen Middlemist
Group Company Secretary +44 20 7399 2760
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 45 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the North America, the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,800 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREASFAEALLEFA
(END) Dow Jones Newswires
January 02, 2024 10:24 ET (15:24 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Hikma Pharmaceuticals (LSE:HIK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024